Leukemia cell mobilization with G-CSF plus plerixafor during busulfan–fludarabine conditioning for allogeneic stem cell transplantation-Reference-Cited by-同舟云学术

Leukemia cell mobilization with G-CSF plus plerixafor during busulfan–fludarabine conditioning for allogeneic stem cell transplantation

Published:2015-04-13 Issue:7 Volume:50 Page:939-946
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Konopleva M,Benton C B,Thall P F,Zeng Z,Shpall E,Ciurea S,Kebriaei P,Alousi A,Popat U,Anderlini P,Nieto Y,Parmar S,Qiao W,Chen J,Rondon G,McMullin B,Wang R-Y,Lu H,Schober W,Woodworth G,Gulbis A,Cool R,Andreeff M,Champlin R

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/bmt201558.pdf

Reference39 articles.

1. van den Brink MRM, Porter DL, Giralt S, Lu SX, Jenq RR, Hanash A et al. Relapse after allogeneic hematopoietic cell therapy. Biol Blood Marrow Transplant 2010; 16: S138–S145.

2. Ninomiya M, Abe A, Katsumi A, Xu J, Ito M, Arai F et al. Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice. Leukemia 2007; 21: 136–142.

3. Meads MB, Gatenby RA, Dalton WS . Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 2009; 9: 665–674.

4. Möhle R, Bautz F, Rafii S, Moore MA, Brugger W, Kanz L . The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood 1998; 91: 4523–4530.

5. Möhle R, Schittenhelm M, Failenschmid C, Bautz F, Kratz-Albers K, Serve H et al. Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia. Br J Haematol 2000; 110: 563–572.

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML;HemaSphere;2023-11-21

2. The results of therapy with venetoclax, daratumumab and plerixafor as part of the conditioning regimen in chemotherapy-refractory acute leukemia in children;Pediatric Hematology/Oncology and Immunopathology;2023-09-30

3. Mobilization-based engraftment of haematopoietic stem cells: a new perspective for chemotherapy-free gene therapy and transplantation;British Medical Bulletin;2023-07-17

4. Targeted Therapy With Venetoclax and Daratumumab as Part of HSCT Preparative Regimen in Children With Chemorefractory Acute Myeloid Leukemia;Transplantation and Cellular Therapy;2023-02

5. Bone Marrow Microenvironment as a Source of New Drug Targets for the Treatment of Acute Myeloid Leukaemia;International Journal of Molecular Sciences;2022-12-29